Cargando…

AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling

BACKGROUND: AAI101 is a novel β-lactamase inhibitor (BLI), active against ESBLs and other β-lactamases. AAI101 combined with cefepime (FEP) is in Phase 2 clinical trials. The objective of this study was to determine differences between AAI101 and tazobactam in their inhibition of selected β-lactamas...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp-Wallace, Krisztina M, Bethel, Christopher R, Barnes, Melissa D, Rutter, Joseph D, Taracila, Magdalena A, Bajaksouzian, Saralee, Jacobs, Michael R, Bonomo, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631055/
http://dx.doi.org/10.1093/ofid/ofx163.924
_version_ 1783269357832372224
author Papp-Wallace, Krisztina M
Bethel, Christopher R
Barnes, Melissa D
Rutter, Joseph D
Taracila, Magdalena A
Bajaksouzian, Saralee
Jacobs, Michael R
Bonomo, Robert A
author_facet Papp-Wallace, Krisztina M
Bethel, Christopher R
Barnes, Melissa D
Rutter, Joseph D
Taracila, Magdalena A
Bajaksouzian, Saralee
Jacobs, Michael R
Bonomo, Robert A
author_sort Papp-Wallace, Krisztina M
collection PubMed
description BACKGROUND: AAI101 is a novel β-lactamase inhibitor (BLI), active against ESBLs and other β-lactamases. AAI101 combined with cefepime (FEP) is in Phase 2 clinical trials. The objective of this study was to determine differences between AAI101 and tazobactam in their inhibition of selected β-lactamases of clinical relevance. METHODS: Isogenic E. coli strains expressing single clinically relevant β-lactamases were tested for susceptibility (broth microdilution MIC) to FEP, FEP/AAI101 and piperacillin-tazobactam (P/T). Periplasmic β-lactamase extracts from selected strains then were used to determine IC(50)s for AAI101 and for tazobactam. β-Lactamases with low IC(50)s for AAI101 were purified, and steady-state inactivation kinetics determined for AAI101 and for tazobactam. RESULTS: AAI101 restored activity of FEP against E. coli strains producing defined β-lactamases, and FEP/AAI101 was more potent than P/T (Table). CONCLUSION: Addition of AAI101 enhances cefepime activity vs. a selected array of β-lactamases expressed in E. coli in an isogenic Background. The inhibitory kinetics of β-lactamases by AAI101 compared with those of tazobactam indicate different mechanisms of β-lactamase inhibition. DISCLOSURES: K. M. Papp-Wallace, Entasis: Grant Investigator, Research grant Allecra: Grant Investigator, Research grant Merck: Grant Investigator, Research grant; Roche: Grant Investigator, Research grant Allergan: Grant Investigator, Research grant M. R. Jacobs, Allecra: Grant Investigator, Research grant Roche: Grant Investigator, Research grant Shionogi: Grant Investigator, Research grant; R. A. Bonomo, Entasis: Grant Investigator, Research grant Allecra: Grant Investigator, Research grant Wockhardt: Grant Investigator, Research grant Merck: Grant Investigator, Research grant Roche: Grant Investigator, Research grant GSK: Grant Investigator, Research grant Allergan: Grant Investigator, Research grant Shionogi: Grant Investigator, Research grant
format Online
Article
Text
id pubmed-5631055
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56310552017-11-07 AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling Papp-Wallace, Krisztina M Bethel, Christopher R Barnes, Melissa D Rutter, Joseph D Taracila, Magdalena A Bajaksouzian, Saralee Jacobs, Michael R Bonomo, Robert A Open Forum Infect Dis Abstracts BACKGROUND: AAI101 is a novel β-lactamase inhibitor (BLI), active against ESBLs and other β-lactamases. AAI101 combined with cefepime (FEP) is in Phase 2 clinical trials. The objective of this study was to determine differences between AAI101 and tazobactam in their inhibition of selected β-lactamases of clinical relevance. METHODS: Isogenic E. coli strains expressing single clinically relevant β-lactamases were tested for susceptibility (broth microdilution MIC) to FEP, FEP/AAI101 and piperacillin-tazobactam (P/T). Periplasmic β-lactamase extracts from selected strains then were used to determine IC(50)s for AAI101 and for tazobactam. β-Lactamases with low IC(50)s for AAI101 were purified, and steady-state inactivation kinetics determined for AAI101 and for tazobactam. RESULTS: AAI101 restored activity of FEP against E. coli strains producing defined β-lactamases, and FEP/AAI101 was more potent than P/T (Table). CONCLUSION: Addition of AAI101 enhances cefepime activity vs. a selected array of β-lactamases expressed in E. coli in an isogenic Background. The inhibitory kinetics of β-lactamases by AAI101 compared with those of tazobactam indicate different mechanisms of β-lactamase inhibition. DISCLOSURES: K. M. Papp-Wallace, Entasis: Grant Investigator, Research grant Allecra: Grant Investigator, Research grant Merck: Grant Investigator, Research grant; Roche: Grant Investigator, Research grant Allergan: Grant Investigator, Research grant M. R. Jacobs, Allecra: Grant Investigator, Research grant Roche: Grant Investigator, Research grant Shionogi: Grant Investigator, Research grant; R. A. Bonomo, Entasis: Grant Investigator, Research grant Allecra: Grant Investigator, Research grant Wockhardt: Grant Investigator, Research grant Merck: Grant Investigator, Research grant Roche: Grant Investigator, Research grant GSK: Grant Investigator, Research grant Allergan: Grant Investigator, Research grant Shionogi: Grant Investigator, Research grant Oxford University Press 2017-10-04 /pmc/articles/PMC5631055/ http://dx.doi.org/10.1093/ofid/ofx163.924 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Papp-Wallace, Krisztina M
Bethel, Christopher R
Barnes, Melissa D
Rutter, Joseph D
Taracila, Magdalena A
Bajaksouzian, Saralee
Jacobs, Michael R
Bonomo, Robert A
AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling
title AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling
title_full AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling
title_fullStr AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling
title_full_unstemmed AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling
title_short AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling
title_sort aai101, a novel β-lactamase inhibitor: microbiological and enzymatic profiling
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631055/
http://dx.doi.org/10.1093/ofid/ofx163.924
work_keys_str_mv AT pappwallacekrisztinam aai101anovelblactamaseinhibitormicrobiologicalandenzymaticprofiling
AT bethelchristopherr aai101anovelblactamaseinhibitormicrobiologicalandenzymaticprofiling
AT barnesmelissad aai101anovelblactamaseinhibitormicrobiologicalandenzymaticprofiling
AT rutterjosephd aai101anovelblactamaseinhibitormicrobiologicalandenzymaticprofiling
AT taracilamagdalenaa aai101anovelblactamaseinhibitormicrobiologicalandenzymaticprofiling
AT bajaksouziansaralee aai101anovelblactamaseinhibitormicrobiologicalandenzymaticprofiling
AT jacobsmichaelr aai101anovelblactamaseinhibitormicrobiologicalandenzymaticprofiling
AT bonomoroberta aai101anovelblactamaseinhibitormicrobiologicalandenzymaticprofiling